SRP6061
VEGFR2 human
recombinant, expressed in insect cells, ≥95% (SDS-PAGE)
Synonym(s):
Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
NACRES:
NA.32
Recommended Products
biological source
human
recombinant
expressed in insect cells
Assay
≥95% (SDS-PAGE)
form
lyophilized
mol wt
116
packaging
pkg of 10 μg
storage condition
avoid repeated freeze/thaw cycles
NCBI accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... VEGFR2(3791)
General description
VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding. The sKDR is purified by proprietary chromatographic techniques.
Vascular endothelial growth factor receptor 2 (VEGFR2), also known as kinase insert domain-containing receptor (KDR), is encoded by the gene mapped to human chromosome 4q12. The encoded protein belongs to the VEGF receptor family.
Biochem/physiol Actions
Vascular endothelial growth factor receptor 2 (VEGFR2) and its ligand VEGF play a vital role in angiogenesis and inflammation. It also facilitates autocrine stimulation of VEGF. VEGFR2 is implicated in progression of various types of cancers such as gliomas, malignant peripheral nerve sheath tumors, triple-negative breast cancer (TNBC) and gastrointestinal stromal tumors (GISTs).
Physical form
KDR was lyophilized from a sterile solution containing 25 mM MES pH 5.5 and 100 mM NaCl.
Preparation Note
Centrifuge the vial prior to opening.
Reconstitution
Reconstitute in sterile water to a concentration not less than 0.1 mg/mL. This solution can then be stored at 4 °C for 2-7 days. For future use for future use; For long term storage it is recommended to add a carrier protein (0.1 % HSA or BSA) then store at ?20 °C. Avoid freeze-thaw cycles.
Other Notes
ASVGLPSVSL DLPRLSIQKD ILTIKANTTL QITCRGQRDL DWLWPNNQSG SEQRVEVTEC SDGLFCKTLT IPKVIGNDTG AYKCFYRETD LASVIYVYVQ DYRSPFIASV SDQHGVVYIT ENKNKTVVIP CLGSISNLNV SLCARYPEKR FVPDGNRISW DSKKGFTIPS YMISYAGMVF CEAKINDESY QSIMYIVVVV GYRIYDVVLS PSHGIELSVG EKLVLNCTAR TELNVGIDFN WEYPSSKHQH KKLVNRDLKT QSGSEMKKFL STLTIDGVTR SDQGLYTCAA SSGLMTKKNS FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP TPQIGEKSLI SPVDSYQYGT TQTLTCTVYA IPPPHHIHWY WQLEEECANE PSQAVSVTNP YPCEEWRSVE DFQGGNKIEV NKNQFALIEG KNKTVSTLVI QAANVSALYK CEAVNKVGRG ERVISFHVTR GPEITLQPDM QPTEQESVSL WCTADRSTFE NLTWYKLGPQ PLPIHVGELP TPVCKNLDTL WKLNATMFSN STNDILIMEL KNASLQDQGD YVCLAQDRKT KKRHCVVRQL TVLERVAPTI TGNLENQTTS IGESIEVSCT ASGNPPPQIM WFKDNETLVE DSGIVLKDGN RNLTIRRVRK EDEGLYTCQA CSVLGCAKVE AFFIIEGA
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zeng Li et al.
Iranian journal of basic medical sciences, 19(4), 411-416 (2016-06-10)
We previously reported a series of quinazoline derivatives as vascular-targeting anticancer agents. In this study, we investigated the mechanism underlying the anti-angiogenic activity of the quinazoline derivative compound 11d. We examined the effects of quinazoline derivative 11d: on vascular endothelial
Yung-Yi Chen et al.
Angiogenesis, 17(1), 207-219 (2013-10-17)
The binding of vascular endothelial growth factor (VEGF) to VEGF receptor-2 (VEGFR-2) on the surface of vascular endothelial cells stimulates many steps in the angiogenic pathway. Inhibition of this interaction is proving of value in moderating the neovascularization accompanying age-related
Magdy A H Zahran et al.
Archiv der Pharmazie, 347(9), 642-649 (2014-06-20)
A series of thalidomide and phthalimide ester analogs were efficiently synthesized from N-chloromethylthalidomide, N-chloromethylphthalimide, and N-(2-bromoethyl)phthalimide derivatives with various biologically important carboxylic acids. The synthesized compounds were purified and characterized by various chromatographic and spectroscopic techniques. The antitumor activity of
Kristi D Lynn et al.
BMC cancer, 10, 397-397 (2010-08-03)
Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis under physiological and pathological conditions. Anti-VEGF therapy is a clinically proven strategy for the treatment of a variety of cancers including colon, breast, lung, and renal cell carcinoma. Since
Eunha Kim et al.
PloS one, 8(11), e81275-e81275 (2013-11-23)
The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that has emerged as an important cancer target. Consequently, a number of different inhibitors varying in specificity are currently in clinical development. However, to date, it has been
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service